Autopsy report · NCT01214096

Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“The same protocol has been launched in United States.”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months after it had already started.
Ran for about 6 months before it stopped.
15 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Zensun Sci. & Tech. Co., Ltd.
Sponsor type: Industry
Conditions: Chronic Heart Failure
Interventions: rhNRG-1; rhNRG-1; rhNRG-1; placebo
Participants: 15
Sites: 4
Countries: China

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.